This page shows the latest Kesimpta news and features for those working in and with pharma, biotech and healthcare.
Kesimpta is the first subcutaneous B-cell therapy that can be self-administered at home for people with RRMS. ... The overall fatal outcome (0.8%) and hospitalisation rates (9.4%) due to COVID-19 in Kesimpta-treated patients were lower than the rates
Rejuvenation of our portfolio continues, from our key brands which include Kesimpta, Leqvio, Zolgensma and the oncology portfolio,” said Novartis CEO Vas Narasimhan.
growth of heart failure drug Entresto (sacubitril and valsartan), monoclonal antibody Cosentyx (secukinumab), gene therapy Zolgensma (onasemnogene abeparvovec), wet AMD therapy Lucentis (ranibizumab) and multiple sclerosis drug Kesimpta (ofatumumab).
The early-stage data bolsters Ocrevus’ claim in the crowded MS market, particularly against Novartis’ Kesimpta (ofatumumab). ... Both Kesimpta and Ocrevus selectively target the immune system’s CD20-positive B cells that damage nerve tissue and
Kesimpta was approved in the EU for the treatment of RMS in adults with active disease at the end of March. ... Kesimpta also met the key secondary endpoints, which included delaying time to confirmed disability progression, in the head-to-head study.
Kesimpta also met the key secondary endpoints, which included delaying time to confirmed disability progression, in the head-to-head study. ... According to Genmab, Kesimpta is the first B-cell therapy that can be self-administered at home using
More from news
Approximately 4 fully matching, plus 3 partially matching documents found.
Self-administered injectables, such as Novo Nordisk’s recently approved therapy for adult growth hormone deficiency (GHD), Sogroya (somapacitan), and Novartis’ much-hyped MS treatment, Kesimpta (ofatumumab), will be tested in
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...